Floatz logo

Thalidomide

Thalassemia Major

National Institute of Blood and Marrow Transplant (NIBMT), PakistanSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Thalassemia Major cohort.

View all 50

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →